Share
+1
Share

Article

February 13, 2018

Avatar

Tiash Saha
1477 views
Roche’s investigational candidate RG7716 showed “clinically meaningful” and “statistically significant” improvements in gaining visual acuity in patients with diabetic macular ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Get 1-Month Free Subscription

Access articles & resources worth up to $4000.

Already have an account?
Categories: BRIEFING, NEWLY PUBLISHED, News from Europe
Tags: , ,
Roche’s investigational candidate RG7716 showed “clinically meaningful” and “statistically significant” improvements in gaining visual acuity in patients with diabetic macular ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Get 1-Month Free Subscription

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Get 1-Month Free Subscription

Access articles & resources worth up to $4000.

Already have an account?

More in BRIEFING

BRIEFING

First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved

2016 founded company, Dova Pharma's first drug, Doptelet received US FDA approval as the first oral treatment option to reduce the risk of blood loss in patients with chronic liver disease.

BRIEFING

Melinta Therapeutics Receives CARB-X Funding to Develop New Antibiotics Against Multiple “Superbugs”

No new class of antibiotics has been approved over the last fifty years. Currently, there are 10 new classes of antibiotics in the CARB-X portfolio, if any one of them reaches to patients, it would be the first new class of antibiotic to be approved, since 1962. Melinta Therapeutics funding.

BRIEFING

First CAR-T GeneTherapy for Pediatric Blood Cancer ‘Kymriah’ Now Treats Adult Patients

Novartis' Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.

BRIEFING

First Drug to Treat Polycystic Kidney Disease Bags FDA Approval

First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.

Most Popular

GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.